Kailos Genetics Announces Co-marketing Agreement with Illumina, Inc. for Pharmacogenetics Solution for Research

HUNTSVILLE, Ala.–(BUSINESS WIRE)–Kailos Genetics, a personalized medicine company offering a leading-edge suite of tools for next-generation sequencing (NGS)-based assays, today announced it has entered into a co-marketing agreement with Illumina, Inc. (NASDAQ: ILMN). Under the terms of the agreement, Illumina will market and promote the Kailos TargetRich™ line of research solutions for pharmacogenetics targets through its commercial channels.

Kailos research solutions under the agreement include: TargetRich PGxComplete™ and Kailos Blue™. TargetRich PGxComplete™ is a research use-only reagent that targets a spectrum of relevant genes and provides insights on effectiveness of more than 100 medications based on the resulting genotype. Kailos Blue is the company’s automated data analysis solution – built with one of the industry’s most advanced computing – and reporting software for using TargetRich reagents. As an Illumina BaseSpace Suite® ecosystem partner, the solution integrates with and pulls data from BaseSpace Sequence Hub which enables customers to, in real-time, stream their data directly from the sequencing instrument.

TargetRich’s automated approach uses a single tube from start to finish with addition-only protocol, which results in a hands-on time of only 75 minutes. The use of unique molecular identifiers offers extremely high levels of sequence quality analysis, delivering results from research experiments at a low cost per targeted base pair.

“TargetRich chemistry and Kailos Blue analysis tools combined with Illumina’s NGS systems and reagents create seamless workflows,” said Brian Pollock, chief executive officer of Kailos Genetics. “The joint solution makes it possible for research laboratories currently standardized on other technologies to convert to NGS. Working with Illumina, we expect to expand the use of NGS solutions to a wider set of laboratories.”

Rob Brainin, vice president and general manager of applied genomics at Illumina added, “We are excited about merging Illumina instruments and reagents with TargetRich reagents to create a solution for our pharmacogenetics research customers. Our collaboration with Kailos is aligned with our mission to provide our customers with innovative solutions at the highest level of quality and to the further adoption of our NGS solutions in the market.”

To learn more about Kailos’ co-marketing agreement with Illumina, as well as the company’s leading-edge suite of tools for next generation sequencing, visit www.kailossolutions.com.

About Kailos

Kailos Genetics is an innovator in next-generation sequencing technologies, with best in class target enrichment chemistries combined with proprietary analysis and reporting software for a complete solution. TargetRich™ provides a simple work flow with robust performance for superior analytic results for next-generation sequencing assays. Kailos Blue is a proprietary, modular laboratory information system with modules for managing samples in the laboratory environment, analytics, and full reporting. Founded in 2010, and based in Huntsville’s HudsonAlpha Institute for Biotechnology, Kailos is committed to providing a simple, trusted and affordable solutions to laboratories looking to launch next-generation sequencing solutions. To learn more, visit www.kailossolutions.com.